PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

NCT00088231 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Agnogenic Myeloid Metaplasia
Chronic Myelogenous Leukemia

Interventions

DRUG: Imatinib Mesylate (Gleevec)
DRUG: PTK 787 (vatalanib)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]